All News

Zovegalisib plus fulvestrant demonstrated an objective response rate of 38.7% and a median progression-free survival of 10.3 months in PIK3CA-mutant HR+/HER2– advanced breast cancer in the ReDiscover trial.

ctDNA-based next-generation sequencing in 236 patients with advanced breast cancer revealed frequent PIK3CA, TP53, and ESR1 mutations, highlighting key mechanisms of endocrine resistance with implications for targeted therapy selection.

The clearance enables the developers to include China-based centers in an ongoing phase 1a/1b trial evaluating the agent in late-stage solid tumors.

Daraxonrasib plus vopimetostat demonstrated a favorable RAS-associated safety profile in patients with MTAP-deleted, pretreated metastatic pancreatic ductal adenocarcinoma.

Sarah Weiss, MD, highlights pivotal updates in uveal melanoma, intratumoral neoadjuvant therapy, and Merkel cell carcinoma from the 2026 ASCO Annual Meeting.

Higher ACE counts were significantly associated with greater symptom burden during anti-estrogen therapy in patients with stage I to IV breast cancer in the Appalachian region of Tennessee.

Dato-DXd plus durvalumab demonstrated robust antitumor activity as first-line treatment for advanced/metastatic triple-negative breast cancer in the phase 1b/2 BEGONIA study, with manageable safety.

While the results from persevERA were not statistically significant, they may support using oral SERDs for patients with ER+/HER2– breast cancer.

The approval of the on-body injector in multiple myeloma follows a positive opinion from the EMA’s Committee for Medicinal Products for Human Use.

Considering the toxicity burden of dual checkpoint inhibition for adjuvant RCC, Saum Ghodoussipour, MD, posited potential alternatives in the space.

Experts discuss abstracts from the 2026 ASCO Annual Meeting that may represent critical advances across multiple myeloma, leukemia, and lymphoma.

A phase 1/1b first-in-human study is evaluating the CNS-penetrant selective ERBB2 inhibitor CGT4255 across multiple tumor types, including HER2-positive breast cancer with brain metastases.

A dual-perspective survey of patients and physicians with metastatic breast cancer identified financial, logistical, and trust-related barriers to trial participation, with greater burden among racial and ethnic minorities.

Saum Ghodoussipour, MD, provided an in-depth analysis of the RAMPART readout, exploring the DFS benefit of a durvalumab/tremelimumab combination in RCC.

Among US women aged 65 and older, foreign-born individuals showed higher self-reported breast cancer prevalence than US-born women, challenging assumptions from studies of younger populations.

Extended drug cessation appears feasible in exceptional responders with HER2+ de novo metastatic breast cancer, with significantly better survival compared with non-exceptional responders.

The safe administration of revumenib among pediatric patients broadens the applicability of results seen with the menin inhibitor.

Catch up on major clinical trials reshaping treatment for brain metastases, Merkel cell carcinoma, cervical cancer, and head and neck cancer all from ASCO 2026.

Support for the NMPA approval of rocbrutinib in relapsed/refractory mantle cell lymphoma was based on findings from the phase 2 ROCK-1 trial.

Data from the phase 3 DeLLphi-304 trial support the European Commission’s approval of tarlatamab in extensive-stage small cell lung cancer.

Data from the phase 3 SENOMAC trial showed that omitting completion ALND led to non-inferior 5-year OS and lower arm morbidity for patients with breast cancer.

A nurse-integrated mobile exercise app showed high usability, 80% exercise adherence, and significant fatigue improvements in a pilot study of adolescents with cancer.

Timothy F. Cloughesy, MD, spoke with CancerNetwork after presenting data from the INDIGO trial, evaluating vorasidenib in IDH1/2-mutant glioma.

Cancer-related survival was similar among patients with PD-L1–positive or PD-L1–negative NSCLC who received durvalumab.

Proactive management of EGFR-mediated toxicities can help to prevent the escalation of grade 1/2 skin toxicities to higher-grade events.

NCCN-indicated germline and somatic testing performance was inconsistent, although rates have been increasing due to concurrent quality improvement efforts.

Saum Ghodoussipour, MD, PhD, dissected the contrasting outcomes between adjuvant durvalumab plus tremelimumab compared with durvalumab alone in RCC.

Real-world data support prospective evaluation of a frontline venetoclax-based regimen in the second line and beyond.

Among patients treated in the PSMAtrack analysis, all had residual PSMA-avid disease following 6 months of systemic therapy for metastatic HPSC.

Retrospective data also showed that immune-related toxicities were more common with BCMA CAR T-cell therapy compared with teclistamab.